Age and acute myeloid leukemia.

By F. Appelbaum, H. Gundacker, D. Head, M. Slovak, C. Willman, J. Godwin, J. Anderson, S. Petersdorf. Blood, 2006

1,364 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/e4b122cb3086e32af50bda410608e4e9f5a2d1a2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. R. DePinho
2. N. Sharpless
3. Julia Salzman
4. Manuel Serrano
5. J. Campisi
6. Ling-Ling Chen

Citations in the corpus

• Acute Myeloid Leukemia: Epidemiology and Etiology (2006, background): “An increased incidence of unfavorable cytogenetics contributes to poor outcome in patients age >56 years, and, within each cytogenetic risk group, treatment outcome deteriorates with age.(15,16) Although incidence rates for AML have been reported to be nearly stable over time among the different age”
• International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. (2015, background): “Older patients considered eligible for IC can have relatively high rates of complete remission (CR); however, no clear survival benefit has been established for IC over less intensive treatment options.(5,10,11) Those patients considered ineligible for IC because of advanced age or poor performance ”
• Efficacy and Biological Correlates of Response in a Phase 2 Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia (2016, neutral): “Objective response rate (CR + CRi) by IWG criteria 6 (19) 4 (33) CR 2 (6) 2 (17) CRi a 4 (13) 2 (17)”
• How stem cells age and why this makes us grow old (2007, background): “Older individuals are more likely to suffer toxicity such as prolonged myelosuppression in response to traditional cytotoxic chemotherapy drugs, suggesting a reduced marrow regenerative capacit”
• Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. (2009, background): “In the study by SWOG(2) 9 of 11 patients over 75 years with a PS of III died within 30 days.”